Supply of Colchicine

A Contract Award Notice
by DEPARTMENT OF HEALTH AND SOCIAL CARE

Source: Find a Tender
Type: Contract (Goods)
Duration: not specified
Value: £10K-£222K

Sector: HEALTH
Published: 07 Apr 2021
Delivery: not specified
Deadline: n/a

Concepts

Location

United Kingdom:

Geochart for 1 buyers and 5 suppliers

1 buyer

Department of Health & Social Care London

5 suppliers

Accord Devon
Hfa Healthcare Products Birmingham
Sigma Pharmaceuticals Watford
Morningside Pharmaceuticals Loughborough
Vertical Pharma Resources Surrey

Description

The Department of Health and Social Care (DHSC) has awarded a contract for the supply of Colchicine for Covid-19.

Total Quantity or Scope

The Department of Health and Social Care conducted a negotiated procedure without prior publication under the Public Contracts Regulations 2015 (as amended) for the supply of Colchicine 500mcg tablets. The contract period expires on 12 April 2021.

Award Detail

1	Accord (Devon) Reference: 007139-2021-1 Value: £222,480
2	Hfa Healthcare Products (Birmingham) Reference: 007139-2021-2 Value: £174,350
3	Sigma Pharmaceuticals (Watford) Reference: 007139-2021-3 Value: £9,940
4	Morningside Pharmaceuticals (Loughborough) Reference: 007139-2021-4 Value: £154,500
5	Vertical Pharma Resources (Surrey) Reference: 007139-2021-5 Value: £50,297

Renewal Options

Option to extend for a further one month from contract expiry date.

Award Criteria

price

CPV Codes

33600000 - Pharmaceutical products

Indicators

Options are available.

Legal Justification

The Coronavirus disease (COVID-19) gave rise to an extremely urgent need for the Authority to purchase a quantity of Colchicine because the Authority needs to be in a position to treat the population as required such that did not give the Authority sufficient time to comply with the standard Open Procedure time scales for this procurement. Accordingly, the Authority used the negotiated procedure without prior publication – Regulation 32(2)(c) – Extreme Urgency Route (i.e. direct award) permitted under the Public Contract Regulations 2015 (as amended) to conduct this procurement. It was imperative to maintain security of supply for public health purposes in the face of high global demand. In these circumstances, a procurement following the usual timescales under the PCR 2015, including accelerated options, was not feasible in order for the DHSC to secure the urgent supply of the Colchicine.